Sigma (ASX:SIG) share price slides 7% to yearly low on guidance update

An earnings downgrade has sent the company's share price deeply into the red today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price is plunging today after the company predicted its earnings will fall this financial year.

The Sigma share price is currently down by 6.67%, trading hands at 49 cents a piece. This is a 52-week low for the company.

Sigma is a pharmacy chain operator and distributor with a network of more than 1,200 pharmacies including well-known brands Chemist King, Amcal and Discount Drug Stores.

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

What did Sigma announce?

In today's release, Sigma predicted its earnings before interest, taxes, depreciation, and amortisation (EBITDA) would drop by 10% in FY22.

The company downgraded its earnings forecast because of impacted sales and operating costs due to a major software update and COVID-19 restrictions. The company implemented a new enterprise resource planning system during the height of pandemic restrictions.

Sigma expects one-off and non-operating costs to be up $25 to $30 million, also proportionally impacting debt.

But while the prediction for FY22 is negative, the company reported 5% growth in September.

And the company also has a positive outlook on future growth overall.

Chairman Ray Gunston said:

Not withstanding this set-back, we remain confident in the future growth profile for Sigma, which was further underlined with the Sigma board recently approving the extension to our new Victorian Distribution Centre in Truganina.

We remain focused on growing our core business, whilst continuing to build on business expansion opportunities across areas such as hospital services, contract logistics and medical devices and consumables…

Sigma expects to announce its FY22 results on 29 March.

Sigma share price snapshot

Over the past 12 months, Sigma shares have dropped almost 17%. The Sigma share price is down 21% year to date. It reached a yearly high of 73 cents on 8 February. At 49 cents apiece, today's price at the time of writing is a yearly low for the company.

Based on today's share price, Sigma has a market capitalisation of roughly $514 million.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »